Skip to content

Advertisement

  • Poster presentation
  • Open Access

Development of a method to involve patients in the determination and appraisal of outcomes in clinical trials

  • Charlotte M.W. Gaasterland1Email author,
  • Marijke C. Jansen-van der Weide1 and
  • Johanna H. van der Lee1
Trials201516(Suppl 1):P15

https://doi.org/10.1186/1745-6215-16-S1-P15

Published: 29 May 2015

Keywords

Pharmaceutical CompanyRare DiseaseRelative WeightTrial DesignDesign Stage

Introduction

Involving patients in the early stages of trial design may be relevant from an ethical point of view, since the patients are those who are most likely to benefit from the research. Also, the quality of the research may benefit from the involvement of patients, who may suggest research questions and outcome measures that are relevant to them, as well as procedures that may lead to better recruitment and retainment. In drug trials, for instance, it may be relevant to ask patients what they expect of a new medication and what they hope the effects are. The instruments used to measure these effects are of pivotal importance for the result of the trial and the subsequent decision-making. In rare diseases the choice of outcomes, and the relative value of several outcomes in a possible composite outcome, is even more important. However, until now there is no standard method to involve patients in the choice and appraisal of outcomes. Therefore, we want to develop a methodology to involve patients in the decisions about relative weights of outcomes in the trial design stage.

Methods

First, we have performed a literature review on patient involvement in research design, and consulted professional patient representatives. Based on these meetings and the literature, we have developed a draft method to involve patients in the determination and weighing of outcome measures. We will elicit feedback from professional stakeholders, e.g. clinical researchers, pharmaceutical companies, regulators, and from a group of patient representatives, which will be used to improve our methods. Subsequently, we will test the methods by applying them in the developmental stage of an actual trial. All contacts with external parties are arranged through the ASTERIX consortium (http://www.asterix-fp7.eu).

Results will become available in 2015.

Authors’ Affiliations

(1)
Pediatric Clinical Research Office Woman-Child Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Copyright

© Gaasterland et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement